|Day Low/High||121.25 / 124.27|
|52 Wk Low/High||67.98 / 182.05|
The NYSE used to be the center of capitalism, but now it's where actual engineering, not financial engineering, is taking place.
Many stocks need rest and small-cap earnings season is rocky, but that doesn't mean the indices are going to see significant downside.
After a negative report on GW's epilepsy treatment, the analyst refused to explain the results with me, bringing more questions than answers about its conclusions.
Shares of the cannabinoid prescription medicine company look to be in a weak state.
Agency has the authority to carve out an exception to existing laws.
Let's see how the charts of GWPH are shaping up.
The charts make ZYNE look bearish and not particularly attractive, so avoid.
The way I do that is by using buy-write option strategies.
Five top marijuana stocks and four CBD plays in this speculative space.
You may want to check out GW Pharmaceuticals and Elixinol Global Limited.
In its first report on cannabis companies, Melius says prices are high.
My trading strategy for GWPH whether you are currently long or want to be.
And why I won't recommend any other stocks in these markets, right now.
The main reason most cannabis-related concerns head north to list their shares is banking.
Despite the current stock market, investors are still looking for ways to play the new legalization of hemp.
A potential great pipeline but let's check the charts.
On Wednesday, Canada becomes the first major economy to legalize the recreational use of cannabis.
These stocks offer some diversification or unique features in the legal-weed space.
It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy. As you go down the marijuana rabbit hole, ...
Sales trends and the potential for stronger versions of prescription cannabis offer medical marijuana providers hope.
It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.
The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.
It's important to know the difference between broken stocks and broken companies.
The game plan is to spot the charts that have more room to run.
Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.
Party leaders will have to work toward merging the two versions of tax reform into one final bill.